BiotechTube

Baricitinib 4 MG Oral Tablet

ApprovedActive
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Frontal Fibrosing Alopecia

Conditions

Frontal Fibrosing Alopecia

Trial Timeline

Apr 22, 2024 → Jul 31, 2027

NCT ID
NCT06240351

About Baricitinib 4 MG Oral Tablet

Baricitinib 4 MG Oral Tablet is a approved stage product being developed by Eli Lilly for Frontal Fibrosing Alopecia. The current trial status is active. This product is registered under clinical trial identifier NCT06240351. Target conditions include Frontal Fibrosing Alopecia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT06240351ApprovedActive

Competing Products

1 competing product in Frontal Fibrosing Alopecia

See all competitors
ProductCompanyStageHype Score
POST TriheptanoinUltragenyx PharmaceuticalPhase 1/2
36

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85